IBRANCE FAQs

Why is IBRANCE transitioning from capsules to tablets?
As part of Pfizer’s ongoing commitment to patients, Pfizer routinely looks for opportunities to better address patient needs and preferences. The IBRANCE tablet formulation offers patients:

• Increased flexibility: Patients can take IBRANCE tablets with or without food, and they can be coadministered with proton pump inhibitors (PPIs) or antacids

• Dose tracking: Tablets come in weekly blister packs that are designed to help patients track their treatment cycles

• Addresses dietary restrictions: The tablet formulation does not contain lactose (dairy) or gelatin

When is the transition happening?
Pfizer will transition to distributing the tablet formulation in April, 2020. At this point, prescriptions will need to specify whether the patient should receive capsules or tablets. Pfizer will continue to supply the capsule formulation for a limited period to enable practices to transition IBRANCE prescriptions to the new tablet formulation. NDC codes for the new formulation are included in the attached trade sheet.

When should I begin to stock IBRANCE tablets?
Please ensure you have some supply of IBRANCE tablets at the time of launch. Keep in mind that because prescriptions will need to specify capsules or tablets, a new prescription will be required if the formulation in stock differs from what is specified in the prescription.

What should I do with my existing inventory of IBRANCE capsules?
Where possible, use up remaining capsule inventory for existing patients that have yet to receive a prescription for the new tablet formulation.

Is there a difference in the active ingredient of IBRANCE?
The tablet formulation is bioequivalent to the capsule formulation. There is no change to the active ingredient, available dosage strengths or dosing schedule.

What should my patients know about the tablet formulation changes?

• IBRANCE tablets can be taken with or without food, are film-coated, and may be administered with proton pump inhibitors (PPIs) or antacids

• Patients should be advised not to crush, chew, or split the tablets before swallowing them

• The new tablets are provided in blister packs. The tablets must be stored in the original blister packs. Pill caddies should no longer be used

• The new tablets do not contain lactose or gelatin
• At launch, the cost for the tablet formulation will be the same as the capsules. We do not expect the new tablet formulation to have any impact on the cost of IBRANCE to patients, access or coverage.

**Will vouchers still be valid?**
Vouchers in the market will be honored and are subject to the same terms and conditions.

**Are there any changes to the way I bill for IBRANCE?**
You will need to bill using the new NDCs for IBRANCE tablets.

New NDCs for IBRANCE include:

• NDC 0069-0688-03 – 125 mg
• NDC 0069-0486-03 – 100 mg
• NDC 0069-0284-03 – 75 mg

**How will the new form of IBRANCE be packaged?**
IBRANCE tablets will be packaged in monthly boxes containing three blister packs of seven tablets each (21 tablets total). The new packaging may require additional shelf space as compared to bottles (see attached trade sheet for dimensions).